Risk factors for lung disease progression in children with cystic fibrosis

Eur Respir J. 2018 Jun 7;51(6):1702509. doi: 10.1183/13993003.02509-2017. Print 2018 Jun.

Abstract

To identify potential risk factors for lung disease progression in children with cystic fibrosis (CF), we studied the longitudinal data of all children with CF (aged ≥5 years) registered in the Dutch CF Registry (2009-2014).Lung disease progression was expressed as a decline in lung function (forced expiratory volume in 1 s (FEV1) % pred) and pulmonary exacerbation rate. Potential risk factors at baseline included sex, age, best FEV1 % pred, best forced vital capacity % pred, genotype, body mass index z-score, pancreatic insufficiency, medication use (proton pump inhibitors (PPIs), prophylactic antibiotics and inhaled corticosteroids), CF-related diabetes, allergic bronchopulmonary aspergillosis and colonisation with Pseudomonas aeruginosaThe data of 545 children were analysed. PPI use was associated with both annual decline of FEV1 % pred (p=0.017) and future pulmonary exacerbation rate (p=0.006). Moreover, lower FEV1 % pred at baseline (p=0.007), prophylactic inhaled antibiotic use (p=0.006) and pulmonary exacerbations in the baseline year (p=0.002) were related to pulmonary exacerbations in subsequent years.In a cohort of Dutch children with CF followed for 5 years, we were able to identify several risk factors for future exacerbations. In particular, the association between PPI use and lung disease progression definitely requires further investigation.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / therapeutic use
  • Aspergillosis, Allergic Bronchopulmonary / complications
  • Child
  • Cystic Fibrosis / drug therapy
  • Cystic Fibrosis / physiopathology*
  • Disease Progression*
  • Exocrine Pancreatic Insufficiency / complications
  • Female
  • Humans
  • Longitudinal Studies
  • Lung / physiopathology*
  • Male
  • Netherlands
  • Proton Pump Inhibitors / therapeutic use
  • Registries
  • Respiratory Function Tests
  • Risk Factors

Substances

  • Anti-Bacterial Agents
  • Proton Pump Inhibitors